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Objectives: The German market access system for drugs have been changed 
significantly in the last years, by introducing a similar focus on benefit assessment 
as in the French system. The research question remains whether they produce 
consistent results in terms of additional benefit (AB) for pharmaceuticals which 
have passed the assessment in both systems. MethOds: The G-BA and IQWiG as 
well as the Transparency Commission (TC) databases were searched systematically 
to identify those products, which have been processed in both systems between 
Jan 2011 and Dec 2013. For further comparison a data grid consisting of 26 items 
for evaluation has been developed including study comparator, primary clinical 
endpoints, health related quality of life inclusion. Results: Overall, 140 new 
therapies have been assessed in France by TC, and 80 in Germany by the G-BA. 
According to inclusion criteria, 44 products could be identified which have passed 
through both systems including 7 orphan drugs. Thirteen products (30%) had no 
AB granted by both Agencies, whereas 9 (20%) were in both cases granted with a 
minor AB, (assuming that “minor” values are equivalent between the two systems), 
amounting to 22/44 cases with a similar resolution. Five cases (11%) showed a 
discrepancy in added benefit, all times TC = no and G-BA = yes. However, varying 
magnitudes appeared to be the greatest difference (n = 17 (39%) remaining drugs), 
conditioned by lacking concordance of both scale grade systems. cOnclusiOns: 
Decisions of the agencies in both countries show partial heterogeneity in driving 
criteria like benefit levels (ASMR and AB). Although the evidence package for initial 
assessment in both countries is largely similar, preliminary results suggest their 
contextualization and scales are different. Further analysis based on results of 
the grid is needed to better assess criteria leading to different benefit levels and 
their reimbursement impact.
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Factors InFluencIng DutcH Drug reImbursement recommenDatIons; 
a Database analysIs
Alleman C.J.M., Spoorendonk J.A., Charokopou M., Hensen M., Heeg B.
Pharmerit International, Rotterdam, The Netherlands
Objectives: In the Netherlands, manufacturers need to apply for reimbursement 
of outpatient drugs on either list 1A (no added benefit) or 1B (added benefit). For 
expensive drugs, hospitals can receive additional reimbursement if the drug is 
included on the expensive drug list (EDL). Pharmacoeconomic evidence is only 
required for list 1B and EDL evaluations. The National Health Care Institute (NZi) 
evaluates submissions and makes (provisional) reimbursement recommenda-
tions to the Dutch government. The aim of this study was to identify explanatory 
variables for the recommendation by NZi. MethOds: A database of published 
evaluations from February-2006 to March-2014 was created, consisting of the 
final reimbursement recommendation and a range of corresponding explanatory 
variables such as the therapeutic indication, clinical and economic characteris-
tics. Univariate analyses were performed to assess the impact of the individual 
explanatory variables on the recommendation by means of odds ratios. Results: 
In total 262 applications were included; the number of positive recommenda-
tions by NZi were 121/122 (99%) for 1A, 77/107 (72%) for 1B and 19/28 (68%) for 
EDL. Pharmacoeconomic analysis was reported in 36/107 (34%) 1B evaluations, 
of which 27 (75%) were recommended. For the EDL category, pharmacoeconomic 
analysis was reported in 20/28 (71%) evaluations, out of which 17 (85%) received a 
positive recommendation. Univariate analyses for the 1B subgroup showed that 
NZi recommendations were significantly (α = 0.05) influenced by clinical trials with 
life-saving primary endpoint (positive), non-inferior trial outcomes compared to 
placebo (negative) and budget impact below € 2,500,000 (positive). Whereas, the 
univariate analyses on EDL evaluations demonstrated that ATC-code L (antineo-
plastic and immunomodulating agents), clinical trials with life-saving primary 
endpoint and reporting of economic analysis outcomes had a significant and posi-
tive impact on the final NZi recommendation. cOnclusiOns: These univariate 
analyses demonstrated that for 1B and EDL evaluations indication, clinical and 
economic factors impact the NZi reimbursement recommendations.
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measurIng extent oF access For nIce HealtH tecHnology assessment 
DecIsIons: trenDs From 2008 to 2013
O’Neill P., Devlin N.
Office of Health Economics, London, UK
Objectives: When assessing trends in NICE HTA decisions it would be useful 
to ascertain their implications on access for groups of technologies. A specific 
issue is to understand the degree of access associated with ‘optimised’ decisions, 
where usage has been restricted to a subgroup of patients relative to the scope of 
the appraisal. Using a previously developed method, we calculate the degree of 
recommended access for medicines and assess trends between 2008 and 2013 by 
therapeutic area and over time. MethOds: In a previously published paper we 
developed a measure, m, to assess access associated with NICE technology opti-
mised appraisal decisions. This was defined as m=(p/P)x100, where m is a measure 
of the level of patient access (0 equals no access, 100 full access), P is the set of 
patients considered in the guidance as potential candidates for treatment (given 
the scope of appraisal and license), and p is the number of patients for whom 
NICE did recommend. Applying measure m to NICE HTA decisions for medicines 
between January 2008 and December 2013 we assess trends by therapeutic area 
and over time. In this paper, to understand trends, we extend the analysis to 
include recommended and not recommended decisions. We assume a recom-
mended decision scores 100 using measure m, a not recommended decision 0, and 
optimised decisions, where not possible to determine m, a score of 50. Results: 
For 201 decisions between 2008 and 2013, on average, m was equal to 52, ranging 
from 37 in 2008 to 57 in 2011. At therapy level, m scored between 38 for cancer 
medicines to 100 for Hepatitis C treatments. cOnclusiOns: The results for this 
period suggest around half of patients have been recommended by NICE to receive 
treatment, relative to scope of appraisal and license. These considerations address 
access not implementation issues.
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a comParIson oF InternatIonal HealtH tecHnology assessment 
systems – Does tHe PerFect system exIst?
Kerr A.1, Todd C.1, Hebborn A.2, Ulyate K.1
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Objectives: There are a number of common elements considered good practice 
in Health Technology Assessment (HTA) that have been published by organizations 
representing the field. These components include: clear processes and decision-
making, including scope for pragmatic approaches and appeal; transparency in 
methodology, value judgments and decisions; and a facility for stakeholder involve-
ment. The objective of this study was to compare international HTA systems to 
rank their performance against the ideal components of HTA. Information was 
also collected on emerging topics such as combined regulatory-payer scientific 
advice, coverage with evidence, evaluation of drug-diagnostic pairs and disinvest-
ment. MethOds: A survey was designed to collect information on the HTA sys-
tems in the United Kingdom (UK), France, Germany, Italy, The Netherlands, Sweden, 
Central Eastern Europe, Canada, Australia, New Zealand (NZ), Korea and Taiwan. 
Questions were grouped under the topics: process, methods, data, societal input 
and transparency. The survey was completed by Roche affiliates with first-hand 
experience working with the HTA system in their country. Results: The majority 
of countries give consideration to rare diseases and low budget impact with leniency 
in decision making and/or process. Transparency in decision-making is lacking in 
many of the countries surveyed. Whilst consumer members sit on decision-making 
committees in several countries, only the UK involves a group of citizens in setting 
the decision making criteria applied by the committee. Combined regulatory-payer 
scientific advice is only available in European countries. Australia is the only country 
to evaluate drug-diagnostic pairings for both costs and outcomes. Only the UK and 
NZ have routine disinvestment reviews. cOnclusiOns: Each country is perform-
ing well in some elements of their HTA system, but none met all the requirements 
of an ideal system. HTA systems can learn from the experiences in other countries 
when considering improvements to processes and efficiency.
PHP223
trenDs In early engagement between InDustry anD Hta: analysIs oF 
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Maignen F.M.1, Osipenko L.1, Gajraj E.1, Chivers R.2
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Objectives: Regulatory Scientific Advice (SA) provided by EMA, FDA, MHRA and other 
agencies is highly demanded by manufacturers but health technology assessment 
(HTA) scientific advice is still far from becoming a routine step in the product develop-
ment cycle. NICE has been running an advisory service for 5.5 years. MethOds: This 
work presents analysis of requests to the programme: types of advice projects, num-
ber and type of requests per company, clinical indication, stage of clinical develop-
ment when the advice is sought, reason for seeking advice and current development 
and regulatory status of products. Results: Between 2009 and 2014 NICE conducted 
109 advisory projects (107 medicinal products and two diagnostic tests). 23 of these 
projects were done in parallel with regulatory agencies and/or other HTA bodies. 
78% of all requests were in the following four therapeutic areas: oncology, neurology, 
rheumatology and cardiology. Majority of products (61%) were in phase II of clinical 
development when advice was sought. At the time of this analysis, 71 products (66%) 
were still in development, 6 (5.5%) were subject of a review for a marketing authorisa-
tion (MA), 8 (7.5%) had received a MA, the authorisation was not granted to 2 products 
(2%) and the clinical development was discontinued in 20 cases (19%). Most products 
that received NICE scientific advice are yet to be referred to the technology appraisals 
programme. cOnclusiOns: Over the last few years, requests for scientific advice 
diversified into personalised medicines, regenerative medicines and products for rare 
and very rare diseases. Most HTA scientific advice requests continue to come from 
top 20 Pharma companies, however we are starting to see an increasing number of 
inquiries and project bookings from small-medium size companies.
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exPlorIng uncertaInty In economIc evaluatIon oF meDIcInes: a 
revIew oF tHe FIrst manuFacturers’ submIssIons to tHe FrencH 
natIonal autHorIty For HealtH (Has)
Ghabri S.1, Hamers F.F.1, Josselin J.M.2, Harousseau J.L.1
1Haute Autorité de Santé (HAS), Saint-Denis La Plaine, France, 2Université de Rennes 1, Rennes, 
France
Objectives: Since October 2013, HAS is required to provide the inter-minis-
terial Economic Committee on Health Care Products (CEPS) with an economic 
evaluation on innovative medicines likely to have a significant budget impact 
on the national health insurance scheme. HAS economic evaluations are based 
on critical appraisals of cost-effectiveness analyses (CEA) submitted by manu-
facturers. Exploration of uncertainty around incremental cost-effectiveness 
ratio is critical to assess the robustness of CEA. Our objective was to assess how 
uncertainty exploration has been undertaken by manufacturers, using HAS 
guidelines on economic evaluation as an analytical framework. MethOds: 
Manufacturers’ submissions assessed by end of May 2014 (n= 13) were reviewed. 
Three sources of uncertainty were considered: uncertainty around model input 
parameters, uncertainty around model structure and methodological uncertainty. 
Tools to explore uncertainty included deterministic sensitivity analysis (DSA), prob-
abilistic sensitivity analysis (PSA), as well as overall compliance with HAS guide-
lines. Results: Model input parameters were the most frequently explored source 
of uncertainty. Both DSA and PSA were systematically used. However, reporting of 
DSA varied substantially across submissions, with frequent lack of justification of 
parameters ranges. Regarding PSA, the choice of distribution was not systemati-
cally justified and lacked consistency across similar parameters. Most submissions 
failed to consider parameters correlations. Exploration of uncertainty around model 
structure was rarely presented. Where applicable, alternative methods for extrapo-
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lating health outcomes were reported in two-thirds of the submissions. However, 
worst-case scenarios were hardly presented. Compliance with HAS guidelines for 
exploring methodological uncertainty (e.g. perspective, discounting, time horizon) 
was fair. However, the choice of the comparator(s)–an essential component of a 
CEA–was considered problematic in nearly 40% of submissions. cOnclusiOns: 
Overall, reporting of DSA and PSA is complying with HAS guidelines. More work is 
needed to explore uncertainty, in particular, to account for correlations between 
model input parameters and to enhance the analysis of structural uncertainty.
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conDItIonal resolutIons In tHe amnog early beneFIt assessment
Assmann G., Schmidt U., Drechsler M., Pfannkuche M.
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
Objectives: Since 2011 the early benefit assessment (EBA) is mandatory to obtain 
reimbursement for new drugs in Germany. By law EBA of the G-BA (Federal Joint 
Committee) can be conditional for a certain period of time. This study explores 
the number, duration and rationale of conditional G-BA resolutions. Furthermore 
the provided, later given (during statement process), accepted and additionally 
requested study data is analysed in this context. MethOds: AMNOG dossiers and 
resolutions of the G-BA including justifications until June 2014 were reviewed for rel-
evant information and analysed with special regard to the submitted and accepted 
study data. Drugs which were directly allocated to a fixed-reference price group 
were excluded. Results: 22 new drugs with conditional resolutions were identified 
(29.3% of all resolutions; 2012: 6, 2013: 10, 2014: 6). Duration varied between 1 and 5 
years (1: 4, 2: 8, 3: 5, 4: 1, 5: 4). Conditional resolutions were most common in cancer 
(n= 13; 59.1%) drugs. 91.0% had at least a benefit (none: 2, minor: 12, considerable: 
6, not quantifiable: 2) in one subgroup. G-BA limited resolutions due to (a) no suf-
ficient data to assess the benefit (n= 9), (b) conditional approval and/or further data 
requests by EMA (European Medicines Agency) (n= 6), (c) expected new study results 
(n= 6), and (d) due to a formal incorrect dossier (n= 1). To date, only vemurafenib 
was assessed again with same result as before. cOnclusiOns: From 2011 on an 
increased number of resolutions and especially cancer drugs were conditional. Only 
in a few cases G-BA defined in the resolution which specific data has to be shown 
in the re-assessment. In these cases the requirements concerning further evidence 
were not part of the G-BA voting. As currently just one drug was re-assessed, no 
conclusions can be drawn how re-assessment changes the extent or certainty of 
additional benefit.
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PrIcIng aDDItIonal beneFIt In germany
Daniel K., Jaksa A., Ho Y.S.
Context Matters, Inc., New York, NY, USA
Objectives: Gemeinsame Bundesausschuss (G-BA) assesses the additional 
benefit of newly-approved drugs compared to the G-BA-determined appropriate 
comparator. As part of the submission, manufacturers provide annual drug cost 
estimates. This research tests whether manufacturers submit higher annual costs 
for drugs that provide greater additional benefit, that is, whether added benefit is 
priced. MethOds: The influence of G-BA’s additional benefit assessment on the 
manufacturer’s estimated per patient annual drug cost was estimated via ordinary 
least squares based on 73 reviews. The model also included controls for the (log) 
size of the target population and the annual cost of the comparator. These vari-
ables were collected from the Federal Gazette publication or the “Beschluss” docu-
ment. Results: Our model explains three-quarters of the variation in annual drug 
cost (R2= .76). Conditional on the target population and the cost of its comparator, 
a drug assessed as having unquantifiable or minor added benefit is estimated to 
have a per patient annual cost about 2 times greater than one with no added benefit 
(p= .02). A drug with the highest assessment, “Considerable additional benefit,” is 
estimated to have an annual per patient cost that is 9 times greater (p< .01). There 
is evidence of a “quantity discount”: doubling the size of the target population is 
estimated to reduce the per-patient annual cost by 18% (p< .01). cOnclusiOns: 
If, as seems plausible, manufacturers’ assessments of their own drugs are aligned 
with G-BA’s assessments, our results are consistent with manufacturers setting 
higher prices for more beneficial drugs. The price a manufacturer uses to estimate 
annual cost represents in effect a proposed allocation of its drug’s benefits between 
itself and patients/payers. This research raises at least two important questions: 
How do manufacturers propose to share the gains and what sharing emerges from 
subsequent price negotiations?
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rIsk oF bIas In trIal-baseD economIc evaluatIons
Adarkwah C.C., Evers S.M., Hiligsmann M.
Maastricht University, Maastricht, The Netherlands
Objectives: The objective of our research is to give first an overview of the risks 
of bias in trial-based economic evaluation, and second to identify how key sources 
for bias can be revealed and overcome (bias-reducing strategies) in future trial-
based economic evaluation in the fields of general practice and health psychol-
ogy. MethOds: A scoping review was performed using PubMed and the NHS 
Economic Evaluation data base. It was complemented with experiences of the 
authors. Sources of bias in trial-based economic evaluation as well as bias-reduc-
ing strategies are discussed. Results: The different forms of bias are presented, 
and assigned to a particular trial phase. A distinction is made between pre-trial 
biases, biases during the trial and biases that are relevant after the actual trial. All 
potential forms of bias are discussed in detail and strategies are shown to detect 
and overcome these biases. cOnclusiOns: In order to avoid bias in trial-based 
economic evaluations, one has to be aware of all of the possible forms of bias and 
all stakeholders have to examine trial-based economic evaluations in a rigorous 
and stringent manner. Our research findings can be helpful in this examination 
as they provide an overview of the possible biases which researchers should take 
into account.
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uk value-baseD assessment: wIll scotlanD’s smc aPProacH It In tHe 
same way?
Hamilton M.L.
Access Partnership, London, UK
Objectives: In May 2010 the UK government set out its intentions to reform the 
current method of pricing branded medicines and introduced a new system of 
value-based pricing (VBP). This was to replace the Pharmaceutical Price Regulation 
Scheme (PPRS) which expired at the end of 2013. With discussion still ongoing, 
and the PPRS renewed up until end of 2018, it has been indicated that VBP will no 
longer relate to medicines’ pricing, but instead will be a reshaping of the Health 
Technology Assessment (HTA) model employed by the UK in its appraisal of new 
medicines, and renamed Value Based Assessment (VBA). As medicine assessment 
is devolved in the UK, performed by NICE in England and the SMC in Scotland, 
we seek to understand whether the SMC will adopt the same approach to VBA as 
NICE. MethOds: The research was conducted through in-depth secondary research 
and interviews with stakeholders, including payers and KOLs, in UK. Results: Both 
NICE and the SMC have indicated they will continue to use QALY as a measurement 
of clinical and cost effectiveness while also incorporating issues such as burden 
of illness and wider societal impact in their assessment. However, their approach 
to conducting such assessments may differ with the SMC suggesting using a new 
system of patient and clinician engagement (PACE), currently in use for the appraisal 
of medicines for end of life or rare conditions (orphans), as a wider process to 
determine Scotland’s requirement for a value based approach to assess all new 
medicines. cOnclusiOns: Manufacturers would be encouraged to closely follow 
the outcomes from the new PACE system, incorporated into the SMC assessment 
for end of life and orphan therapies, to ensure readiness for the introduction of 
VBA in Scotland.
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DIscrePancy between natIonal Drug recommenDatIons anD local 
uPtake In tHe sweDIsH InPatIent sector
McGee M.A.1, Izmirlieva M.2, Ando G.2
1IHS Life Sciences, London, UK, 2IHS, London, UK
Objectives: The current study seeks to assess discrepancies between national 
inpatient drug recommendations issued through the cost-effectiveness pilot project 
(Klinikläkemedelsprojektet) in Sweden and local uptake reflected by Stockholm 
Country Council´s (SLL) procurement activity. MethOds: Secondary research 
investigated the 15 inpatient drug recommendations issued by the national New 
Pharmaceutical Therapies group (Nya Lakemedels Terapier, NLT) in 2013 and com-
pared these against the SLL’s 2014 procurement list. Results: In 2013, the NLT 
group issued a total of 15 recommendations for products in a variety of therapeu-
tic areas (TA). Out of these, ten gained positive national decisions, 50% of which 
were for oncology drugs. Of those recommended, cancer drug pertuzumab (Perjeta; 
Roche, Switzerland) saw the highest incremental cost-effectiveness ratio (ICER), at 
SEK2,565,000 (USD383,730) per quality-adjusted life year (QALY) - greatly exceed-
ing the informal cost-effectiveness threshold of SEK800,000 in Sweden. There was 
a significant discrepancy in the number of nationally recommended drugs (ten) 
in 2013, versus the SLL uptake (two) by 2014. The two recommended products 
subsequently procured were Roche´s (Switzerland) ophthalmology drug ranibi-
zumab (Lucentis) and Takeda´s (Japan) oncology therapy brentuximab vedotin 
(Adcetris). cOnclusiOns: The Swedish government is contemplating making the 
Klinikläkemedelsprojektet permanent, and as such the alignment between national 
and local level priorities is a critical component of its integrity. The results show 
that eight nationally recommended products had not been procured, indicating 
that there is still a discrepancy between those recommendations and uptake at 
the local level, based on the current data. One explanation for the discrepancy 
could be attributed to the funding system, where local payers are responsible for 
funding inpatient drugs.
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Hta aPProacH In Italy. structure, metHoDs, anD Process oF veneto 
regIon’s evaluatIon oF PHarmaceutIcal eFFectIveness unIt (unItà DI 
valutazIone Dell’eFFIcacIa Del Farmaco, uveF)
Young K.E.1, Urbinati D.2, Toumi M.3
1Creativ-Ceutical, Milan, Italy, 2Creativ-Ceutical, Luxembourg, Luxembourg, 3University  
Aix-Marseille, Marseille, France
Objectives: Veneto leads the nation in terms of better health status and phar-
maceutical expenditures within budget. This study aimed to assess the region’s 
Health Technology Assessment (HTA) approach (structure, methods, and process 
of conducting HTA) by observing Evaluation of Pharmaceutical Effectiveness Unit’s 
(UVEF) evaluations on drugs, the concomitant Regional Technical Commission 
(CTR) decisions on formulary inclusion, and the evidences considered. MethOds: 
We reviewed all HTA reports in the UVEF website evaluating the HTA dimensions 
assessed, if they were in line with the HTA scoping document by the Regional 
Decrees (2008), and changes over time. Further, this research evaluated the presence 
of explicit explanations behind each CTR decision. Results: 223 HTA listings were 
retrieved in the UVEF website (2004-2011). 50.23% were published before the actual 
establishment of UVEF (2008) and were probably labelled HTA retrospectively. Fewer 
dimensions were assessed in the earlier documents and the most extensive changes 
were seen in 2008. The most assessed dimensions were Efficacy, Safety, and Costs 
and the least assessed were Budget Impact Analysis, Target Population, Place in 
therapy, and Assessment of Innovation. The Regional Decrees (2008) were impactful 
on the structure of the HTA reports, however these are still not fully compliant to 
the scoping document. A total of 72 CTR decisions were found in the website from 
2009 to 2011. On average, 92% of all CTR documents have a documented explana-
tion behind each decision. cOnclusiOns: The HTA approach in Veneto is evolving 
towards the development of uniformity in the documents and a single transparent 
approach. The upward trend of attaching CTR decisions with explicit explanations 
